WO1998032455A1 - Extrait d'aiguilles de pin et son utilisation - Google Patents

Extrait d'aiguilles de pin et son utilisation Download PDF

Info

Publication number
WO1998032455A1
WO1998032455A1 PCT/CN1997/000006 CN9700006W WO9832455A1 WO 1998032455 A1 WO1998032455 A1 WO 1998032455A1 CN 9700006 W CN9700006 W CN 9700006W WO 9832455 A1 WO9832455 A1 WO 9832455A1
Authority
WO
WIPO (PCT)
Prior art keywords
pine needle
treatment
group
needle extract
extract
Prior art date
Application number
PCT/CN1997/000006
Other languages
English (en)
French (fr)
Inventor
Ling Ji
Original Assignee
Ling Ji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ling Ji filed Critical Ling Ji
Priority to KR10-1999-7006766A priority Critical patent/KR100529793B1/ko
Priority to CA002279261A priority patent/CA2279261A1/en
Priority to EP97902147A priority patent/EP1013278B1/en
Priority to PCT/CN1997/000006 priority patent/WO1998032455A1/zh
Priority to US09/355,389 priority patent/US6329000B1/en
Priority to AU15884/97A priority patent/AU734851B2/en
Priority to JP53145598A priority patent/JP2001508777A/ja
Priority to DE69734163T priority patent/DE69734163T2/de
Publication of WO1998032455A1 publication Critical patent/WO1998032455A1/zh
Priority to HK00104348A priority patent/HK1025246A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/618Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/15Pinaceae (Pine family), e.g. pine or cedar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • A61K36/428Trichosanthes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the present invention relates to pine needle extract and its medical application, especially to the treatment of hypertension and coronary heart disease, as well as the pharmaceutical composition containing pine needle extract and its medical use.
  • Pine needles are also known as pine leaves and Latin name is Folium Pini.
  • pine needles are the leaves of the Pinaceae genus (Pinusae), and their plant sources are Pinus abuleaformis carr, Pinus massoniana Lams, and Pinus Yunanensis Franch.
  • Pinusae Pinaceae genus
  • Pinus abuleaformis carr Pinus abuleaformis carr
  • Pinus massoniana Lams Pinus Yunanensis Franch.
  • pine needles have been used for many years as an ingredient in certain medicines, such as the Chinese Traditional Medicine Dictionary, which contains transplants for the treatment of bruises, puffiness, eczema, scabies, prevention of influenza, meningocele, and treatment of chronic bronchitis and insomnia.
  • Chinese Traditional Medicine Dictionary which contains transplants for the treatment of bruises, puffiness, eczema, scabies, prevention of influenza, meningocele, and treatment of chronic bronchitis and insomnia.
  • pine needles were used as one of the components.
  • pine needles have a long history as ingredients of medicines, there are no reports of pine needles alone in the treatment of hypertension, coronary heart disease, angina pectoris, arrhythmia, cerebral infarction, hyperlipidemia, hyperviscosity, hyperpolyemia, arterial disease ⁇ 5 changes in the role of Alzheimer's disease, Alzheimer's disease, sudden deafness and other conditions, nor has pine needles or their extracts been combined with other substances to treat the above conditions.
  • pine needle extracts can be used to treat hypertension, angina pectoris, myocarditis, arrhythmia, cerebral infarction, hyperlipidemia, diabetes, hyperviscosity, hyperpolyemia, arteriosclerosis, elderly Dementia, sudden deafness and other diseases have received satisfactory results.
  • pine needle extracts can be used to treat hypertension, angina pectoris, myocarditis, arrhythmia, cerebral infarction, hyperlipidemia, diabetes, hyperviscosity, hyperpolyemia, arteriosclerosis, elderly Dementia, sudden deafness and other diseases have received satisfactory results.
  • one of the objects of the present invention is to provide a pine needle extract for treating various diseases, such as coronary heart disease, angina pectoris, myocarditis, arrhythmia, hypertension, hyperlipidemia, hyperviscosity, high poly Anemia, diabetes, cerebral infarction, cerebral arteriosclerosis, arteriosclerosis, dementia and sudden deafness, etc .;
  • Another object of the present invention is to provide a pharmaceutical composition for treating a disease.
  • Another object of the present invention is to provide a method for treating a variety of conditions.
  • Another object of the present invention is the use of pine needle extracts in the treatment of diseases.
  • a bark extract has a light brown to dark brown color when in a solid state. There is a maximum absorption peak around 242 nm.
  • Figure 1 shows the thin-layer chromatography effect of the pine needle extract of the present invention.
  • Fig. 2 is an ultraviolet-visible light absorption chart of the pine needle extract of the present invention.
  • Figure 3a shows the dependence of pine needle extract on vasodilation and dose concentration in the presence of endothelium.
  • Fig. 3b shows the relationship between the vasodilator effect and the dose concentration of the control group in the presence of endothelium.
  • Figure 3c shows the relationship between the vasodilating effect of the extract and the dose concentration of the extract.
  • Fig. 3d shows the relationship between the vasodilation effect and the dose concentration of the systolic thrombocyte in the control group after endothelial removal.
  • Figure 4 shows the combined effect of pine needle extract and Pueraria lobata extract on vasodilation in the presence of endothelial cells.
  • a pine needle extract has a light ochre to dark brown color when in a solid state, is soluble in water, and has a maximum absorption peak at 242 ⁇ 1 nm in ultraviolet-visible light.
  • pine needle extract is effective for a variety of conditions. These diseases include, for example, myocarditis, coronary heart disease, angina pectoris, arrhythmia, hyperlipidemia, hyperviscosity, hyperpolyemia, cerebral infarction, diabetes, cerebral arteriosclerosis, dementia, arteriosclerosis, and processes Deafness, etc. Pine needle extract is especially effective for hypertensive blood pressure, hyperlipidemia, hyperviscosity, hyperpolyemia,
  • the pine needle extract of the present invention can be extracted from pine needles by a conventional method.
  • Conventional methods include, for example, water extraction, water extraction and alcohol precipitation, alcohol (such as ethanol) extraction, and the like, and water extraction is preferred.
  • the source of pine needles can be pine needles collected from various pine trees, such as larch, Pinus tabulaeformis, Pinus massoniana, Cedar, Pinus sylvestris, Pinus sylvestris, Pinus yunnanensis and Pinus sylvestris. Pine leaves.
  • the solid pine needle extract is light brown to dark cotton color. The intensity of the color depends on the drying method used. It is soluble in polar solvents such as water and ethanol. When using UV-visible light for reference, it is found that the pine needle extract has a maximum near 242nm. Absorption peaks; when identified by thin-layer chromatography, their R f values are 0.93 and 0.78,
  • a pharmaceutical composition comprising a therapeutically effective amount of pine needle extract and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutically acceptable vehicle or excipient is a conventionally used vehicle or excipient.
  • a method for treating a disease comprising administering to a patient a therapeutically effective amount of a pine needle extract of the present invention, such diseases including hypertension, diabetes, coronary heart disease, angina pectoris, arrhythmia, myocarditis, hyperlipidemia, hyperviscosity, Hyperpolyemia, cerebral infarction, dementia, arteriosclerosis, and sudden deafness, among others.
  • diseases including hypertension, diabetes, coronary heart disease, angina pectoris, arrhythmia, myocarditis, hyperlipidemia, hyperviscosity, Hyperpolyemia, cerebral infarction, dementia, arteriosclerosis, and sudden deafness, among others.
  • the pine needle extract of the present invention can also be combined with other drugs to treat the above-mentioned diseases or other diseases.
  • it can be taken in combination with a calcium supplement to play a comprehensive role in lowering blood pressure, blood lipids, blood sugar, blood viscosity and platelet aggregation rate, and regulating calcium metabolism.
  • the pine needle extract of the present invention can also be combined with other components to treat the above diseases.
  • These components can be, for example, kudzu root, uncaria, nacre powder, keel, tapioca, oyster, ginkgo biloba, salvia, safflower, chuanxiong, yew leaf, melon, and so on.
  • a formulation includes pine needles and kudzu root, wherein the ratio of pine needles to kudzu root is 3 : 1 to 5: 2, preferably 3: 1 to 4: 1.
  • the formula of pine needles and kudzu root can be used to treat the above-mentioned diseases.
  • the formula further includes pearl layer powder, wherein the ratio of pine needles and pearl layer powder is: 20: 1 ⁇ 2: 1.
  • Preferred pine leaves: Pueraria: Pearl layer powder is 18: 6: 9. Adding pearl layer powder to the formula can increase the regulation of calcium metabolism,
  • Kudzu root is the root of the legume Pueraria Lobata (Wmd.)
  • Ohwi. Nacre powder is a powder processed from the inner part of the crustacean crested crested crested owl Cristaria plicata (Leach), or back shell dentate Anadonta woodiana (Lea.). Ge Ge, pearl powder are widely available from the market.
  • a pharmaceutical composition includes an effective amount of an extract of pine needles and kudzu root and a pharmaceutically acceptable plant or excipient.
  • a method for treating a disease includes administering to a patient a therapeutically effective amount of an extract of the formula for treating the above-mentioned diseases.
  • Extracts of pine needles and kudzu roots can be obtained by extracting pine needles and kudzu roots together, or by separately extracting pine needles and kudzu roots and mixing the extracts.
  • the pharmaceutical composition of the present invention can be used for gastrointestinal administration, topical administration, etc., and can be made into various different dosage forms. Such as tablets, oral liquids, powders, pills, capsules, injections (including intravenous infusions), topical lotions, pastes, tinctures, powders, granules, etc.
  • the dosage of the pine needle extract of the present invention is 1 to 3 g / time for an adult, preferably 1 to 2 g / time three times a day when administered orally, and 0.5 to 1 lg / time for a child (aged 5 to 14 years). three times.
  • a child aged 5 to 14 years.
  • the pine needles can be processed as a whole, or they can be cut or ground before being processed. Add an excess of ice to the pine needles, at least four times, and preferably eight to nine times by weight. It is then heated for cooking. The cooking time is 1 to 2 hours, and it is 1.5 hours. After cooking, it is filtered and the filtrate is concentrated to obtain a dark brown concentrated liquid.
  • the filtrate obtained after filtration can be re-added with water for the second digestion.
  • the amount of water added should be at least 3 times', preferably 6-7 times, and the cooking time should be 0.5-1.5 hours, preferably 1 hour.
  • the filtrate obtained through filtration can be combined with the filtrate obtained in the previous time and concentrated together.
  • the concentrated solution can be further dried to obtain a light to dark brown powder.
  • Various methods can be used for drying, such as spray drying, vacuum drying, and freeze drying. Generally, the drying method with high operating temperature will make the color of the ochre powder powder darker, and the identification test of pine needle extract
  • UV spectrophotometer Shiadzu UV-260 type
  • Wavelength range 200-500nm
  • the degree of absorption at the wavelength of maximum absorption is 0.6 ⁇ 0.8 'according to spectrophotometry "Chinese Pharmacopoeia” (1995 edition Appendix VA) measured in the UV wavelength range 200 ⁇ 5 00nm - visible Europium (see Figure 2) shows that there is a maximum absorption peak at a wavelength of 242 ⁇ lnm.
  • Pine needle extract decoction, concentrated or water-extracted spray-dried powder after alcohol precipitation
  • SHRsp spontaneously hypertensive rats
  • mice 30 healthy male Wistar rats, of which 20 were operated to form a kidney and a clip of renal hypertension according to the Goldblatt method; 30 spontaneously hypertensive rats (SP), male,
  • the blank control group (SP) was given steamed water 2ml / 100g body weight / time;
  • the positive control group was given compound apocynum tablets 1.08g / kg / time;
  • the small dose group was given pine needle extract powder 0.83g / kg / time;
  • the large dose group was given pine needle extract powder 3.3g / kg / time.
  • the right common carotid artery was isolated, the distal end was ligated, and the heparinized catheter was inserted proximally, and connected to a five-channel physiological instrument to monitor blood pressure and heart rate.
  • the abdominal cavity was opened and administered by the duodenum. Observe before and after administration 30 minutes' 1 hour, 2 hours, 3 hours changes in blood pressure and heart rate.
  • Pine 4 ⁇ extract has a slight decrease in blood pressure in the normal group only at 30 minutes, and returns to the original level after 1 hour (P> 0.05), 2 no significant change in blood pressure in the blank group (P> 0.05); 3 medication in the positive control group After 30 minutes, the blood pressure started to drop, reaching a peak within 2 hours, and the highest drop rate was 8.1 ⁇ 1.22%, which was statistically significant compared with the pre-medication (PO.05). 4 In the low-dose group, the blood pressure decreased at 30 minutes after the administration, and reached a peak within 2 hours. The highest decrease rate was M.3 ⁇ 2.32% (renal) and 15.6 ⁇ 2.17% (SP), which was significantly different from that before the treatment (P ⁇ 0.001).
  • pine needle extract has no significant effect on blood pressure in normal rats, but can significantly reduce arterial blood pressure in SP and renal hypertension rats. It begins to take effect at 30 minutes and reaches a peak in 2 hours. The effect lasts for more than 3 hours and is dose-dependent. The antihypertensive effect is stronger than that of compound apocynum.
  • Wistar rats 1 normal control group were given pine needle extract powder 1.6g kg / day, SP rats were given one group per 10, 2 blank control group were given distilled water 2ml / 100g body weight per day, 3 compound prescription Apocynum group, 1.08g / kg / day, 4 small dose group: powder 0.83g kg / day, 5 medium dose group: pine needle extract powder 1.6g / kg / day, 6 large dose group: pine needle extract powder 3.3g / kg / day, intragastric administration once a day, each intragastric volume is 2ml / 100g body weight, 3 weeks as a course of treatment, the blood pressure and general conditions of the rats are measured before and after the administration, and the external blood pressure and carotid blood pressure are measured after the treatment is stopped, and A linear regression correlation test was performed, and the experimental results were expressed as mean soil standard deviation (SD).
  • SD mean soil standard deviation
  • Pine needle extract has a good antihypertensive effect on spontaneously hypertensive rats (SP), which is dose-dependent, but has no effect on normal blood pressure. Its antihypertensive effect is stronger than that of compound apocynum tablets (P ⁇ 0.001). SP rats treated with pine ⁇ extract had normal activity, appetite, and increased weight gain.
  • the treatment group took 15ml / time of oral pine needle extract, 3 times a day, one month as a course of treatment; the control group was composed of 2 apocynum tablets, 3 times a day, one month as a course, and measured before and after taking the medicine.
  • the oral solution contains 1.6 g of pine needle extract per 15 ml).
  • mice 60 Beijing big-eared white rabbits, all male, weighing 1.5-2Kg,
  • Cholesterol is produced by Beijing Chemical Reagent Company, propyl stone oxopyrimidine tablets, West German products, each 50mg, lard is homemade; the pine needle extract powder of the present invention (referred to as pine needle powder), inositol nicotinate Lipid tablets, products of Beijing Second Pharmaceutical Factory, each 0.2, total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein kits are products of Beijing Zhongsheng Biotechnology.
  • the total cholesterol was measured by CHOD-PAP method, triglyceride was GPO-PAP method, and high-density lipoprotein was osmotungstate-magnesium (PTA-Mg2 +) precipitation method.
  • PTA-Mg2 + osmotungstate-magnesium precipitation method.
  • Low-density lipid Protein ethylene sulfuric acid (PVS) one-step precipitation method the instrument is Hitachi 7150 automatic biochemical analyzer.
  • the (2) group decreased, and the other groups increased.
  • the (4) and (5) groups were more significant (P ⁇ 0.01), and the increase rate was highest in the (5) group (P ⁇ 0.01).
  • Pine needle extract can reduce serum total cholesterol, triglycerides and low-density lipoprotein, and increase high-density lipoprotein for hyperlipidemia caused by high-fat meal.
  • the prevention group has the best effect, followed by the high-dose group.
  • Pine needle extract has therapeutic and preventive effects on hyperlipidemia.
  • pine needle extract regulates parathyroid function test
  • mice 5 healthy male Wistar rats, weighing 320-360g, 10 spontaneous hypertension (SP) rats, male, 170-270g,
  • mice were divided into (1) normal control group, (2) SP blank control group, and (3) SP treatment group.
  • Wistar rats were (1) the normal control group was given pine needle powder 1.5g / Kg / day; the SP rats were randomly divided into 5 groups, each of which was 5 groups; (2) a blank control group, with 2ml of distilled water daily / 100g body weight, intragastric administration once a day; (3) compound apocynum group, 1.08g / Kg / day, (4) small dose group, pine needle powder 0.8g / Kg / day, (5) medium dose group, pine needle powder On the day of 1.5g / Kg, (6) the high-dose group, ten powders of 3.0g / Kg / day, intragastric administration once a day, each intragastric volume is 2ml / 100g body weight, three weeks as a course of treatment. Blood was taken from the eye veins after anesthesia before and after the administration, and the serum was separated by cryocentrifugation (-4 'C), and the serum
  • Pine needle extract has a certain effect on the function of parathyroid gland in spontaneously hypertensive rats (SP). After 3 weeks of treatment, the PTH of SP rats decreased significantly, and the CT significantly increased. Although there were differences from the normal control group, but Compared with the blank control group, the PTH decline rate and CT rise rate were significantly different. Pine needle extract has a certain regulatory effect on the parathyroid gland of SP rats. Fourth, pine needle extract improves the hemorheological effect.
  • mice 25 healthy Beijing big-eared rabbits, male, weighing 1.5-2kg.
  • Sample grouping (1) ADP plus osmic acid buffer group, ADP2umol / L, phosphate buffer solution is 0.2mol / L; ( 2 ) ADP plus equal volume salvia miltiorrhiza solution; ( 3 ) ADP plus equal volume Kudzu root extract solution; ( 4 ) ADP plus equal volume of pine leaf extract liquid; (5) ADP plus equal volume of the composition liquid.
  • the patients were 37 to 75 years old, 52 males and 35 females, including 36 patients with coronary heart disease, 37 with hypertension, 9 with cerebral infarction, 45 with hyperlipidemia, and 12 with diabetes (some patients had 2 or 2 44 cases in the control group, 18 cases of coronary heart disease, 21 cases of hypertension, 3 cases of cerebral infarction, 32 cases of hyperlipidemia (some patients with concurrent 2 or more diseases), stopped before the test Use drugs such as persantin, salvia, aspirin, calcium stagnation agents that affect hemorheology for more than a week,
  • the treatment group was taken orally ⁇ ! Shi Oral Liquid 15ml (containing pine needle extract 1.6g), three times a day, one month as a course; the control group was treated with compound Danshen tablets three times a day, one month as a course of treatment. Check the hemorheological parameters before and after treatment, perform a significant test on the mean of the results, and t test between groups.
  • Pine needle extract has a significant therapeutic effect on patients and animals with hyperviscosity and hyperglycemia, which can reduce blood sedimentation, hematocrit, plasma and whole blood ratio by 4%. Viscosity, reduce platelet aggregation rate, which is of great significance for promoting blood circulation, preventing and treating thrombotic diseases and improving the body's microcirculation, for the treatment of myocardial infarction, coronary heart disease, angina pectoris, cerebral infarction, hypertension, arteriovenous thrombotic diseases, Sudden deafness and blood stasis provide the theoretical basis. Fifth, the clinical trials of pine needle extract expansion, anti-angina pectoris and anti-arrhythmia,
  • Angina pectoris control The total number of angina pectoris episodes in 42 patients in the treatment group before and after taking the medication decreased from 395 before treatment to 128 (PO.001). In all cases, no symptoms worsened after treatment, the total efficiency reached 92.8%; and The number of angina pectoris episodes in the control group decreased from 215 before treatment to 108 (P ⁇ 0.05).
  • Pine needle extract can significantly control the number of angina pectoris attacks in patients with coronary heart disease, improve ischemic electrocardiogram changes, control the occurrence of arrhythmia (early ventricle), and significantly reduce serum total cholesterol, slightly reduce triglycerides, increase High-density lipoprotein, lower TXB 2 and increase PGI 2 increase coronary blood flow, reduce myocardial oxygen consumption and myocardial afterload, and protect ischemic myocardium.
  • pine needle extract anti-aging increase cerebral blood flow effect
  • the animal test and clinical test of the composition (hereinafter referred to as the composition) of the pine needle and pueraria extract of the present invention are described below. Check.
  • vasodilatation test of isolated perfusion proved that the composition had an arterial dilatation effect, and this effect was endothelium-dependent and dose-dependent.
  • the vasodilator effect of the composition gradually increases with increasing dose concentration, with a maximum diastolic rate of 96%, as shown in Figure 4.
  • Treatment of hypertension In all cases, other antihypertensive drugs were discontinued for 1 week before treatment, and blood pressure was measured once a day. The average blood pressure of 5 consecutive times (non-same day) after discontinuation of other antihypertensive drugs was treated as blood pressure before treatment.
  • Blood pressure after treatment Blood pressure is measured once a day after the start of treatment, and the average blood pressure is measured five times on the 16th to 20th days after treatment (not on the same day). The average blood pressure is the blood pressure after treatment. In each case, blood and urine were checked before and after treatment. Routine, liver and kidney function, blood potassium, sodium, chlorine, blood lipid, blood glucose, electrocardiogram, etc.
  • Efficacy determination criteria Significant effect: Diastolic blood pressure decreased> 1.33kpa after treatment, and fell to normal or decreased above 2.67kpa; Effective: Although the diastolic blood pressure decreased after treatment did not reach 1.33kpa, it has fallen to normal or decreased 1.33-2.53kpa. If it is systolic hypertension, a decrease in systolic blood pressure> 4kpa is also effective; Ineffective: the blood pressure drop after treatment does not meet the above standards,
  • ECG and blood biochemical changes before and after treatment 88 cases in 2 groups had 10 premature ventricular premature beats, 8 cases of atrial premature beats, 4 cases of complete left bundle branch block, 7 cases of complete right bundle branch block, and left ventricular hypertrophy 10 cases, 16 cases with II, III, avF, V 4 -V 6 ST-T ischemic changes, 12 cases with V 4 -V 6 ST-T ischemic changes improved after treatment, atrial Premature beats disappeared in 8 cases, and ventricular premature beats disappeared in 7 cases.
  • the changes in serum potassium, sodium, chlorine, and blood glucose were not significant before and after treatment.
  • the composition can significantly reduce the essential hypertension and renal hypertension.
  • the antihypertensive effect occurs within 30 minutes after taking the drug, and reaches a peak in 2 hours. The duration of the effect exceeds 3 hours.
  • the antihypertensive effect becomes dose-dependent. It can maintain blood pressure in the normal range, and also has a lipid-lowering effect. It is especially suitable for patients with hypertension and hyperlipidemia. There were 44 cases of medication without any side effects. The total effective rate was 77% (Table 15). Table 13 General conditions of the two groups Compare
  • Treatment group According to the diagnostic criteria of myocarditis, 11 cases of viral myocarditis and 5 cases of rheumatic myocarditis were selected as the treatment group (a total of 16 cases), including 9 males and 7 females, and 6 to 17 patients (1 1.6 ⁇ 2.8). Years old), ECG showed 10 cases of myocardial ischemia, 9 cases of arrhythmia (6 cases showed tachycardia, 4 cases of frequent premature beats, 2 cases of bradycardia).
  • Control group 8 cases of viral myocarditis, 4 cases of rheumatic myocarditis, a total of 12 cases, including 5 males and 7 females, aged 4 to 16 years (9.1 ⁇ 2.6 years). There were 9 cases of myocardial ischemia and 7 cases of arrhythmia (5 cases of tachycardia and frequent premature beats, 2 cases of bradycardia). '
  • the treatment group was given 1.5g of the formula 3 times a day; the control group was treated with conventional therapy: intravenous drip of 10% glucose 500ml daily, plus vitamin C / 3g, ATPMOmg, coenzyme 100u, once a day, intramuscular injection assisted tread Q101 / Day, 30 days is a course of treatment.
  • Rheumatic myocarditis in both groups is given conventional anti-rheumatic treatment.
  • 1 clinical data 110 cases were randomly divided into 40 cases of the treatment group and 70 cases in the control group, treatment group, 70 cases in 50 men and 12 women, aged 40--67 years, mean age 55 years, high serum cholesterol (TC) There were 41 cases of hyperemia and 55 cases of hypertriglyceridemia (TG).
  • TC high serum cholesterol
  • TG hypertriglyceridemia
  • 28 were males and 12 were females, aged 40 to 66 years, with an average age of 54 years, and 30 patients with hyperTC and TG each.
  • the sex, age, and symptoms of the two groups were basically similar and comparable.
  • the treatment group was formulated with 1.5g 3 times a day for 1 month.
  • 1.1 Target According to the WHO diagnostic criteria, the subjects selected for treatment of primary hypertension, coronary heart disease, angina pectoris, hyperlipidemia and hyperviscosity were divided into three groups.
  • Angina pectoris group 40 cases, 21 males and 19 females, aged 45 to 79 years, with an average of 59.8 ⁇ 15.2 years old, 26 patients (65%) and 14 patients (35 %).
  • Hyperlipidemia and hyperviscosity group 65 patients, 42 males and 18 females, aged 55.3 ⁇ 5.0 years,
  • Treatment method Stop using other antihypertensive drugs, anti-angina pectoris or lipid-lowering drugs, take formula 1 ⁇ 1.5g / time, 3 ⁇ days, course of treatment 4 ⁇ 6 weeks, if accompanied by left ventricular hypertrophy, you can use Yi Nalin, such as angina pectoris, can use nitrates or quick-acting Jiuxin pills, etc., other conventional treatments remain unchanged
  • Angina pectoris group The symptomatic effects of electrocardiogram and the different types of angina pectoris are shown in Table 19 and Table 20.
  • Hematocrit The specific viscosity of whole blood and plasma decreased by 27.1, 16.6% and 24.6%, respectively, and there was a significant or very significant difference between the indexes before and after treatment (P ⁇ 0.05 or 0.01), indicating that the formula did lower blood pressure, lower cholesterol, and triglyceride. Lipids, low-density lipoprotein cholesterol, hematocrit, whole blood and plasma specific viscosity, increase high-density lipoprotein cholesterol, protect the heart, and relieve angina.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

松针提取物及其应用 技术领域
本发明是关于松针提取物及其医药应用, 尤其是在治疗高血压和在治疗冠心病心 病的应用, 以及含松针提取物的药物组合物和其医药用途。
背景技术
松针又名松叶, 拉丁名 Folium Pini。 特别是松针为松科 (Pinaceae)松属 (Pinus)植物 的叶, 其植物来源为油松 (Pinus abuleaformis carr), 马尾松 (Pinus massoniana Lams)、 云 南松 (Pinus Yunanensis Franch)等。 在中国松科植物约有 20种 10变种, 引种栽培的有 16种 2变种.
在中国, 许多年来认为松针可以作为某些药物的配料, 例如《中药大辞典》 中收 栽了治疗跌打损伤, 浮肿、 湿疮疥癣, 预防流感、 流脑, 治疗慢性支气管炎和失眠症 等古今验方, 其中松针被用作组分之一。
尽管松针作为药物的配料已有悠久的历史, 但未见报道松针单独具有治疗高血 压、 冠心病、 心绞痛、 心律失常、 脑梗塞、 高脂血症、 高粘血症、 高聚血症、 动^ 5更 化症、 老年痴呆症、 突发性耳聋等病症的作用, 也未见将松针或其提取物与其它物质 组合, 用于治疗上述病症.
经过多年的研究, 本发明人发现松针提取物可用于治疗高血压、 心绞痛、 心肌炎、 心律失常、 脑梗塞、 高脂血症、 糖尿病、 高粘血症、 高聚血症、 动脉硬化症、 老年痴 呆症、 突发性耳聋等病症, 收到了满意的效果。 发现了松针的一些可靠的新用途, 发明概述
因此, 本发明的目的之一是提供一种松针提取物, 用于治疗多种疾病, 例如冠心 病、 心绞痛、 心肌炎、 心律失常、 高血压病、 高脂血症、 高粘血症、 高聚血症、 糖尿 病、 脑梗塞、 脑动脉硬化症、 动脉硬化症、 老年痴呆症和突发性耳聋等等;
本发明的另一个目的是提供一种治疗疾病的药物组合物。
本发明的另一个目的是提供一种治疗多种病症的方法。
本发明的另一个目的是关于松针提取物在治疗疾病中的应用.
本发明的其它目的, 将在对本发明的描述中体现。
根据本发明, 一种杠 提取物, 固态时呈浅棕色至深棕色, 紫外-可见光光讲中 在 242nm附近有最大吸收峰。
一种松针提取物, 用于治疗心肌炎、 冠心病、 心绞痛、 心律失常、 高血压、 高脂 血症、 高粘血症、 高聚血症、 脑梗塞、 老年痴呆症、 糖尿病、 脑动脉硬化症、 动眛硬 化症和突发性耳聋症等等. 附图简要说明
图 1为本发明松针提取物的薄层层析效果。
图 2为本发明松针提取物的紫外 -可见光吸收图。
图 3a表示在内皮存在时, 松针提取物的血管扩张作用与剂量浓度的依赖性关系。 图 3b表示在内皮存在时, 对照组开搏通的血管扩张作用与剂量浓度的关系。 图 3c表示去 (¾皮后杠 †提取物的血管扩张作用与剂量浓度的关系,
图 3d表示去内皮后对照组开搏通的血管扩张作用与剂量浓度的关系。
图 4表示在内皮存在时, 松针提取物和葛根提取物对血管扩张的综合作用。 发明详述
根据本发明, 一种松针提取物, 固态时呈浅椋色至深棕色, 可溶于水, 紫外-可 见光光谙中在 242±lnm处有最大吸收峰。
本发明人发现松针提取物对多种病症均有疗效。 这些疾病包括, 例如, 心肌炎、 冠心病、 心绞痛、 心律失常、 高脂血症、 高粘血症、 高聚血症、 脑梗塞、 糖尿病、 脑 动脉硬化症、 老年痴呆症、 动脉硬化症和突发性耳聋症等等。 松针提取物尤其是对高 血压、 高脂血症、 高粘血症、 高聚血症有疗效,
本发明的松针提取物可以用常规的方法从松针中提取。 常规的方法有, 例如, 水 提法、 水提醇沉法、 醇(如乙醇)提法, 等等, 优选水提法。 松针的来源可以是采自 各种松树的松针, 如落叶松、 油松、 马尾松、 雪松、 萚松、 红松、 云南松和黑松等等, 优选来自油松、 马尾松和云南松的松叶。
固态松针提取物为浅棕色至深棉色, 颜色的深浅取决于所采用的干燥方法, 溶于 极性溶剂如水、 乙醇等. 用紫外 -可见光借鉴别时, 发现松针提取物在 242nm附近有 最大吸收峰; 用薄层层析方法鉴别时, 其 Rf值分别为 0.93和 0.78 ,
一种药物组合物, 包括治疗有效量的松针提取物和药物上可接受的载体或赋形 剂. 该药物上可接受的栽体或赋形剂为常规使用的栽体或赋形剂。
一种治疗疾病的方法, 包括给病人服用治疗有效量的本发明的松针提取物, 这些 疾病包括高血压、 糖尿病、 冠心病、 心绞痛、 心律失常、 心肌炎、 高脂血症、 高粘血 症、 高聚血症、 脑梗塞、 老年痴呆症、 动脉硬化症和突发性耳聋症等等。
本发明的松针提取物也可以与其它药物配伍, 治疗上述疾病或其它疾病。 例如, 可以与补钙剂配合服用, 起到降血压、 降血脂、 降血糖、 降低血液粘度和血小板聚集 率和调节钙代谢等的综合作用。
本发明的松针提取物还可以与其它組份组合, 用于治疗上述疾病。 这些组份可以 是, 例如, 葛根、 钩藤、 珍珠层粉、 龙骨、 珍珠粉、 牡蛎、 银杏叶、 丹参、 红花、 川 芎、 赤柏叶、 瓜蒌等等。
根据本发明, 一种配方包括松针和葛根, 其中松针与葛根的比例为 3: 1 ~ 5: 2 , 优选 3 : 1 - 4: 1。 松针和葛根的配方可以用于治疗上述疾病, 根据本发明, 所述配方还包括珍珠层粉, 其中松针与珍珠层粉的比例为: 20 : 1 ~ 2: 1。 优选 松叶: 葛根: 珍珠层粉为 18: 6: 9 . 在配方中加入珍珠层粉, 可以增加钙代谢的 调节作用,
葛根为豆科植物野葛 Pueraria Lobata(Wmd.)Ohwi的根。 珍珠层粉为蚌科动物褶纹 冠蛑 Cristaria plicata( Leach), 或背壳无齿蛑 Anadonta woodiana(Lea.)等的壳内层部分 加工而成的粉末。 葛 ■、 珍珠层粉均来源广泛, 市场上可以得到。
根据本发明, 一种药物组合物, 包括有效量的松针和葛根的提取物和药物上可接 受的栽体或赋形剂.
一种治疗疾病的方法, 包括给病人 ^ ^用治疗有效量的所述配方的提取物, 用于治 疗上述疾病。
松针和葛根的提取物可以由松针与葛根一起提取得到, 也可以将松针和葛根分别 提取后将各提取物混合后得到。
本发明的药物组合物可以胃肠用药、 局部用药等, 可以制成各种不同剂型。 如片 剂、 口^ -液、 粉剂、 丸剂、 胶嚢剂、 注射剂 (包括静脉输液剂) 、 外用洗剂、 膏剂、 酊剂、 散剂、 冲剂等,
本发明松针提取物的给药剂量, 口服时, 成人为 1 ~ 3g/次, 优选 1 ~ 2g/次每日 三次, 儿童( 5岁以上- 14岁以下) 为 0.5~lg/次, 每日三次。 作为举例, 下面我们详细描述用水提法制备本发明的松针提取物。
取原料松针. 松针可以整体加工, 也可以切段或磨粉后再进行处理' 优选把松针 切段后再处理。 向松针中加入过量的氷, 至少要 4倍以上, 最好为 8 - 9倍(重量)。 然后加热进行煮提, 煮提的时间为 1 ~ 2小时, 优逸 1.5小时, 煮提后, 进行过滤' 并将滤液浓缩, 得到深棕色的浓缩液。
过滤后得到的滤出物可以再次加水进行第二次煮提. 加水量至少为 3倍以上' 最 好为 6 ~ 7倍, 煮提的时间为 0.5~1.5小时, 优选 1小时。 第二次煮提后, 经过滤得 到的滤液可以合并入前次得到的滤液一起浓缩,
如果需要, 浓缩液可以进一步干燥, 得到浅至深棕色粉状物. 干燥可以采取多种 方法, 如喷雾干燥, 真空干燥和冷冻干燥等等。 一般操作温度高的干燥方法会使得到 的椋色粉状物的颜色偏深, 松针提取物的鉴别试验
1、 薄层层析( TLC ) 的鉴别
称取干燥的松针提取物粉 5g , 加入乙醚浸泡(时时振摇) 2次, 每次 1小时,
30ml , 滤过, 滤液合并, 回收乙醚至干, 加少量乙醚溶解, 转入 lml容量瓶中, 加乙 醚至刻度, 摇匀, 作为供试品溶液, 照薄层色谘法《中国药典》 ( 1995版附录 VIB ) 试验, 吸取上述供试品溶液 10~20ul , 点于以羧甲基纤维素纳粘合剂的硅胶 G薄层板 上, 以石油醚: 乙酸乙酯( 4 : 1 )为展开剂, 展开 12cm , 取出, 晾干, 喷以 20 % 硫酸乙醇溶液, 置 105 'C加热至斑点颜色出现。 在供试品色谱中, 具有相同紫红色的 两个主斑点( Rf值分别为 0.93和 0.78 ) (见附图 1 )。
2、 紫外线光讲的鉴别
取松针提取物粉过 60 目筛, 于 50 ~ 55 'C干燥 3小时, 移置硅胶干燥器内保存 备用。
称取经上述预处理的松针提取物粉 2g (精确到 O.Olg ) , 置 50ml具塞三角烧瓶 中, 加石油醚超声提取 3次, 每次 15ml , 30分钟, 滤过, 残渣挥干溶剂, 再加氯仿 超声提取 3次, 每次 15ml , 30分钟, 滤过, 滤液合并, 回收氯仿至干, 加少量氯仿 溶解, 转入 10ml容量瓶中, 加氯仿至刻度, 摇匀, 作为供试品液。
采用紫外分光光度仪(曰本岛津 UV - 260型),
狭缝宽度: lnm 波长增量: 2nm
波长范围: 200-500nm
吸收度范围: 0 ~ 1
将供试品液经适当稀释后, 使最大吸收波长处的吸收度为 0.6〜0.8 ' 照分光光度 法《中国药典》 ( 1995版附录 VA )在波长 200 ~ 500nm范围内测定其紫外-可见 光谙 (见附图 2 ) , 表明在波长 242±lnm处有最大吸收峰。 一、 松针提取物的降压作用
松针提取物(煎剂, 浓缩或水提醇沉后喷雾干燥粉剂)对原发性高血压、 肾性高 血压病人及自发性高血压大鼠 (SHRsp)。 二肾一夹肾性高血压大鼠有显著的降压作 用, 此降压作用呈剂量依赖性。
(一')松针提取物的急性降压试验'
( 1 )材料和方法:
实验动物: 健康雄性 Wistar大鼠 30只, 其中 20只按 Goldblatt法经手术形成一肾 一夹肾性高血压; 自发性高血压大鼠 (SP)30只, 雄性,
药品: 松针提取物粉, 复方罗布麻片.
正常对照組给予松针提取物粉 l.6g/kg/次;
空白对照组 (SP)给予蒸铺水 2ml/100g体重 /次;
阳性对照组给予复方罗布麻片 1.08g/kg/次;
小剂量组给予松针提取物粉 0.83g/kg/次;
大剂量组给予松针提取物粉 3.3g/kg/次。
将动物麻醉后分离右颈总动脉, 结扎远端, 近端插入肝素化导管, 与五导生理仪 相连, 监测血压及心率, 打开腹腔, 由十二指肠给药, 观察用药前及用药后 30分' 1 小时, 2小时, 3小时血压及心率变化。
( 2 ) 结果: (见表 1 )
Figure imgf000008_0001
*P<0.05 **P<0.01
松 4†提取物对①正常组血压仅在 30 分时有轻度下降, 1 小时后恢复原水平 (P>0.05), ②空白组血压无明显变化 (P>0.05); ③阳性对照组用药后 30 分血压开始下 降, 2小时达高峰, 下降率最高为 8.1±1.22%, 与用药前比有统计意义 (PO.05), ④小 剂量組于用药后 30分血压下降, 2小时达高峰, 下降率最高为 M.3±2.32% (肾性) 和 15.6±2.17%(SP), 较用药前有非常显著差异 (P<0.001), ⑤大剂量组 2小时血压下降 最显著, 为 18.6±2.07% (腎性〕和 17.6±1.98%(SP), 与本组治疗前和其余各组治疗后 2小时血压相比, 差别非常显著 (P<0.001)。
小结: 松针提取物的急性降压试验表明, 松针提取物对正常大鼠血压无明显影 响, 但可显著降低 SP和肾性高血压大鼠的动脉血压, 30分开始出现作用, 2小时达 高峰, 作用持续 3小时以上, 且剂量依赖性, 降压作用强于复方罗布麻。
(二)松针提取物的长期降压试验
1、 材料和方法
健康 Wistar大鼠 10只, 自发性高血压大鼠( SP ) 50只, 雄性, 药品(同急性 降压试验),
方法: Wistar大鼠①正常对照组, 给予松针提取物粉 1.6g kg/日, SP大鼠每 10 只为一只组, ②空白对照组, 每曰给予蒸馏水 2ml/100g体重 /日, ③复方罗布麻组, 1.08g/kg/日, ④小剂量組: 粉 0.83g kg/日, ⑤中剂量组: 松针提取物粉 1.6g/kg/ 日, ⑥大剂量组: 松针提取物粉 3.3g/kg/日,一日一次灌胃, 每次灌胃容积为 2ml/100g 体重, 3周为一疗程, 用药前后测定大鼠血压和一般情况, 停药后测定体外血压和颈 动脉血压, 并进行直线回归相关性检验, 实验结果以均数土标准差( SD )表示, 组间进行检验,
2、 结果: (见表 2 )
表 2 松针提取物对 SP大鼠的长期降压作用
Figure imgf000010_0001
*P<0.05 ***P<0.001 经松针提取物粉治疗后比较, 大鼠一般情况正常, 空白对照组体重增长较少(平 均 2g ) , 而松针提取物大、 中、 小剂量組平均增 6.7g , 松针提取物对正常对照组血 压无何影响(P>0.05), 小剂量组治疗后血压下降率为 30.7±0.93%, 中剂量组为 38.82+3.68%, 大剂量组为 48.22±1.16%, 与治前比有非常显著差别 (P<0.001), 与空白 组及罗布麻组比较有显著差异( P<0.001 ) 治后 MAP 与体外血压呈显著正相关 (r=0.903 , t=8.899 , Ρ<0.001)。
结论: 松针提取物对自发性高血压大鼠( SP )有良好的降压作用, 呈剂量依赖 性, 而对正常血压无影响, 其降压作用强于复方罗布麻片 ( Ρ<0.001 ) 。 经松†提取 物治疗的 SP大鼠活动、 食欲正常, 体重增加较多。
( 三)松针提取物的临床降压试验
1、 方法:
选择住院病人 106例, 门诊病人 38例, 经详细询问病史, 查体及实验室检查, P T
- 9 - 按 1987年 WHO高血压专家委员会诊断标准, 确诊原发性高血压 ( EH ) 124例, 其 中 I期 EH38例, II期 71例, III期 15例, 肾性高血压 20例, 受检前停用降压剂, 利尿剂及血管扩张剂一周以上, 分为治疗组和对照組。
治疗組口服松针提取物的口服液 15ml/次, 每日 3 次, 一个月为一疗程; 对照组 复方罗布麻片 2片 /次, 每日 3次, 一个月为一疗程, 服药前后分别测 3次非同日清晨 血压, 取平均值为治前和治后血压. (该口服液每 15ml含松针提取物 1.6g ) 降压疗效评定标准:
( 1 )显效: ①舒张压下降 lOmmHg以上, 并达到正常范围; ②舒张压虽未降至 正常, 但已下降 20mmHg或以上, 具备其中一项。 ( 2 ) 有效: ①舒张压下降不及 lOmmHg , 但已达到正常范围; ②舒张压较治疗前下降 10 ~ 1 mmHg , 但未达到正 常范围; ③收缩压较前下降 30mmHg以上, 具备其中一项, ( 3 )无效: 未达到以上 标准者。
2、 结果: (见表 3 )
表 3 松针提取物对高血压病人的疗效
Figure imgf000011_0001
*Ρ<0·05 **Ρ<0.01 ***Ρ<0.001 两组年龄及治疗前血压无何差异( Ρ>0.05 ) , 治疗后与本组治疗前血压相比, 以 治疗组血压下降最显著( PO.001 ) , 对照组有轻度下降 (Ρ<0.05), 组间较有显著性 差异( Ρ<0.001 ); 治疗组显效率及有效率均比对照組显著( Ρ<0.001或<0.05 ) 试验中还观察到, 治疗组的患者经治疗后头晕、 头痛、 胸闷、 心悸失眠和五心烦 热等症状明显减轻或消失, 显效率达 52.41~75.22%, 明显高于对照组 (P<0.001); 未见 不良反应, 血、 尿、 便常规及肝肾功能未见异常改变; 20例肾性高血压患者肾功能 有不同程度改善, 尿素氮、 血肌酑下降, 同位素肾图示 ' 脏排泄功能较前改善 結论: 松针提取物对原发性高血压和肾性高,血压有显著的治疗作用, 其降压和緩 解临床症状, 改善肾功能作用明显优于对照组(复方罗布麻) 。 二、 松针提取物的降脂试验
1、 材料及方法
实验动物: 北京大耳白兔 60只, 均为雄性, 体重 1.5-2Kg ,
药品、 试剂: 胆固醇由北京化学试剂公司生产, 丙基石巟氧嘧啶片, 西德产品, 每 片 50mg , 猪油为自制; 本发明的松针提取物粉, (简称松针粉) , 烟酸肌醇脂片, 北京第二制药厂产品, 每片 0.2 , 总胆固醇、 甘油三酯、 高密度脂蛋白、 低密度脂蛋 白试剂盒均为北京中生生物工程技术公司产品。
方法: 将大耳白兔正常飼养 10天后, 随机分为 5组, 每组 10只, 清晨空腹由耳 缘静脉取血查血脂, 同日开始给予高脂饮食; 胆固醇 2g/Kg/日, 猪油 0.5g Kg/日, 丙 基 氧嘧啶 12.5mg Kg/日, 第 4組预防组在高脂餐的同时, 给予松针粉 0.75g/Kg/日, 高脂餐 15天后再次空腹取血, 称重, 停用高脂餐, 给予正常饲料饲养, ( 1 ) 空白 对照组,每日濯胃蒸馏水 10ml , ( 2 )阳性对照组,给予烟酸肌醇脂 OJg/Kg/日, ( 3 ) 小剂量组, 给予松针粉 0.25g/Kg/日, ( 4 )预防组, 继续按原剂量给予松针粉, 共给 药 30天, ( 5 ) 大剂量组给药剂量为 1.5g/Kg/日, 均溶于 10ml蒸饱水中, 灌胃法给 药,一日一次。给药第 15日清晨空腹取血复查血脂,总胆固醇采用 CHOD - PAP法 , 甘油三酯为 GPO - PAP法, 高密度脂蛋白为璘钨酸-镁( PTA - Mg2+ ) 沉淀法, 低密度脂蛋白乙烯硫酸( PVS )一步沉淀法, 仪器为日立 7150型自动生化分析仪。
2、 结果(见表 4)
松针提取物对高脂血症动物血脂的影响 (X±SD)
Figure imgf000013_0001
表 4续 松针提取物对高脂血症动物血脂的影响 (X ± SD)
Figure imgf000014_0001
* P<0.05 **P<0.01 ***P<0.001
由表中可见, 服高脂餐前各组血脂各项指标均无统计学差异( P>0.05 )服高脂餐 后 ( 4 )预防组总胆固醇、 甘油三酯和低密度脂蛋白均明显低于其它 4个组, 并有显 著的统计学意义 (PO.001); 治疗后各组的总胆固醇、 甘油三酯和低密度脂蛋白均有下 降, ( 2 ) 、 ( 3 ) 、 ( 4 ) 、 ( 5 ) 组与 ( 1 ) 空白对照组比较有显著的统计学差 异, 其中以( 4 )预防组下降最显著 (P<0.001), 各组的下降率与空白组( 1 ) 比较亦 有明显差别, ( 3 )、 ( 4 ) 、 ( 5 )组优于( 2 )组, 甘油三酯下降率( 2 )组与
( 1 )组无差异, 与 ( 3 )、 ( 4 )、 ( 5 )组有差异, 以 ( 5 )组最显著 (P<0.001); 低密度脂蛋白下降率以( 3 )、 ( 5 )组为最显著 (P<0.001);治疗后高密度脂蛋白 ( 1 )、
( 2 )组下降, 其它各组均增高, ( 4 )、 ( 5 )组更显著( P<0.01 ) , 升高率以 ( 5 ) 組最高 ( P<0.01 ) 。
结论:
松针提取物对高脂餐所致动物高脂血症, 可降低血清总胆固醇、 甘油三酯及低密 度脂蛋白, 升高高密度脂蛋白, 预防组疗效最佳, 大剂量组次之, 证明松针提取物对 高脂血症有治疗和预防作用. 三、 松针提取物调节甲状旁腺功能试验
1、 材料及方法
实验动物: 健康雄性 Wistar大鼠 5只, 体重 320 - 360g , 自发性高血压( SP ) 大鼠 10只, 雄性, 170 - 270g ,
实验试剂: 松针提取物粉, 甲状旁腺激素( PTH )、 降钙( CT )放射免疫药盒 为曰本荣岩公司产品.
方法: 将动物为 ( 1 ) 正常对照组、 ( 2 ) SP空白对照组、 ( 3 ) SP治疗组, 每 5只为一组。 Wistar大鼠为 ( 1 ) 正常对照组给予松针粉 1.5g/Kg/日; 将 SP大鼠 随机分为 5组, 每 5只为一组; ( 2 )空白对照组, 每日以蒸 水 2ml/100g体重, 一 日一次灌胃; ( 3 ) 复方罗布麻组, 1.08g/Kg/日, ( 4 ) 小剂量组、 松针粉 0.8g/Kg/ 日, ( 5 ) 中剂量组、 松针粉 1.5g/Kg日, ( 6 ) 大剂量组、 十粉 3.0g/Kg/日, 一 日一次灌胃, 每次灌胃容积为 2ml/100g体重, 三周为一疗程。 于用药前后麻醉后眼球 静脉取血, 冷冻离心 ( - 4 'C )分离血清, 以放射免疫法测定血清 PTH、 CT .
2、 结果: 松针提取物对大鼠 PTH、 CT的影响
Figure imgf000016_0001
由表 5中可见, 治疗前( 1 )正常对照组与 ( 2 ) , ( 3 ) 两组 PTH、 CT值有 显著差异,治疗后 ( 3 a PTH有明显下降, CT有显著上升,但( 1 )组仍与 ( 2 )、 ( 3 )组间有差异 (P<0.05); 治疗后 ( 3 PTH下降值和 CT上升值与 ( 1 )、 ( 2 ) 组有明显差异 (PO.05和<0.001).
结论:
松针提取物对自发性高血压大鼠( SP ) 的甲状旁腺功能有一定影响, 经治疗 3 周后, SP大鼠的 PTH明显下降, CT明显升高, 虽然与正常对照组存在差异, 但其 PTH下降率和 CT上升率与空白对照组比较, 存在显著统计学差异。 松针提取物, 对 SP大鼠的甲状旁腺有一定调节作用, 四、 松针提取物改善血液流变学效应.
(一)、 松针提取物体外血小板聚集抑制试验
1、 材料及方法
实验动物: 健康北京大耳兔 25只, 雄性, 体重 1.5-2kg .
试剂及仪器, 松针提取物, 丹参注射液 (lml含生药 2g), 葛根提取物(lml含生药 2g), 二磷 苷二钠 (ADP20ug/200uI), 0.2mol/L磷酸緩冲液 (300mg/ml), 枸椽酸钠液 (3.8%),2%硅油-石油醚液, MG - 176型血小板聚集仪, 台式平衡自动记录仪, 圓 形比色杯 (型号: CHRONO - LOG312 # ),硅化离心管, 微量进样器。
方法 取禁食 10 - 14h大耳白兔耳缘静脉血 3ml , 置于硅化离心管中, 血与枸 椽酸钠抗凝剂之比为 9: 1 , 混匀后离心 800i m , 4 分钟取上层液为富血小板血浆 (PRP), 余血再离心 (3000rpm)10分钟, 取上清液为贫血小板血浆 (PRP), 在 37。C恒温 条件下以 BORN比浊法进行血小板聚集测试, 比色杯中血浆容量为 250ml, 测试时间 为 5 分钟。 样本分组: (l)ADP 加碓酸緩冲液组, ADP2umol/L , 磷酸缓冲液为 0.2mol/L; (2)ADP加等容量丹参液; (3)ADP加等容量葛根提取物液; (4)ADP加等容 量松叶提取物液; (5)ADP加等容量该组合物液。
2、 结果 (见表 6)
由表 6可见, 以 ADP加磷酸緩冲液为基准,(2)ADP加丹参组,(3)ADP加葛根组, (4)ADP加松叶组和 (5)ADP加组合物血小板聚集率明显下降, 后 4組下降率比(1)组有 非常显著差异, 尤以 (4)、 (5)组为著, Γ聚集抑制率达 74.56-80.06%, 5,最大聚集率 (4)、 (5)组亦与 (2)、 (3)组有明显差异。
3、 小结
体外血小板聚集抑制试验表明, 组合物、 松针提取物与葛根提取物对血小板聚集 率有显著的抑制, 此作用明显强于等浓度丹参液, 对家兔的体外血小板聚集抑制作用 1,时最强。 几种药物比较对血小板聚集的抑制作用强度依次为: 组合物组>松叶组 >葛 根组 >丹参组, 试验表明, 松针与葛根的组合物和松针提取物对于防治血小板聚集, 治疗血瘀症有重要作用。
表 6 体外血小板聚集抑制试验
Figure imgf000018_0001
*P<0.05 **P<0.01 ***P<0.001
(二)松针提取物改善血液流变学的临床试验
1、 资料和方法:
患者为 37 ~ 75岁, 男性 52例, 女性 35例, 其中冠心病人 36例, 高血压 37例, 脑梗塞 9例, 高脂血症 45例, 糖尿病 12例 (部分病人并发 2种或 2种以上疾病) ; 对照组 44例, 冠心病 18例, 高血压病 21例, 脑梗塞 3例, 高脂血症 32例 (部分为 并发 2种或 2种以上疾病患者), 受试前停用潘生丁、 丹参、 阿斯匹林、 钙阴滞剂等 对血液流变学有影响的药物一周以上,
治疗组口服^!十口服液 15ml (含松针提取物 1.6g ) , —日三次, 一个月为一程; 对照组服复方丹参片 3片, 一日三次, 一个月为一疗程。 治疗前后检查血液流变学参 数, 对结果均数进行显著性检验, 组间 t检验.
2、 结果:
经治疗后松针组血沉减慢, 压积减少, 血浆比粘度及全血比粘度(高切、 低切) 均明显改善, 血小板聚集率亦明显降低。 见表 7、 表 8 . 松针提取物对高粘血症者血液流变学的影响 (X±SD)
Figure imgf000019_0001
*P<0.05 **P<0.01 ***P<0.001
松针提取物对高聚血症患者血小板聚集率的影响 (X±SD)
Figure imgf000020_0001
*P<0.05 ***P<0.001 结论: 松针提取物对于高粘、 高聚血症的患者及动物均有显著的治疗作用, 可降 4氐其血沉、 血球压积、 血浆和全血比粘度, 降低血小板聚集率, 这对于活血化瘀, 防 治血栓性疾病改善机体微循环有重要意义, 为该药治疗心肌梗塞, 冠心病、 心绞痛, 脑梗塞、 高血压病、 动静脉血栓性疾病, 突发性耳聋和血瘀症等提供了理论依据, 五、 松针提取物的扩冠、 抗心绞痛及抗心律失常临床试验,
对 42例冠心病人采用松针口服液每次 15ml (含松针提取物 1.6g ) , 3 日治 疗, 治疗前后检查心电图、 血脂、 血栓素 B2(TXB2), 6-酮 -PGF^PGL), 对照组口服 消心痛 10ml/次, 日, 一个月为一疗程。
结果: (见表 9、 10、 1 1 )
表 9 松针提取物对冠心病患者心率和 TXB2、 PGI2的影响
Figure imgf000021_0001
**P<0.01 ***P<0.001
表 10 松针提取物对冠心病患者血脂的影响
总胆固醇 甘油三酯 高密度脂蛋白 分组 n 治前 治后 治前 治后 治前 治后 治疗组 42 6.96 4.82*** 2.10 1.63 * 1. 16 1.43
±1.06 ±0.92 ±0.82 ±0.66 ±0.30 ±0.32 对照组 25 6.04 5.89 1.98 1.84 1.21
±1.13 ±1.02 ±0.76 ±0.81 ±0.36
*Ρ<0.05 ***Ρ<0.001
+1 ― 寸 松针提取物对冠心病患者心电图的影响
Figure imgf000022_0001
在治疗组的 42例冠心病人中, 7例为频发性室性早搏, 经松针提取物治疗后 6例早 搏明显减少, 1例无变化; 为频发性房性早搏, 1例显效; 慢性冠状动脉供血不足者 24 例, 心电图,缺血性 ST - T改善者 16例; 陈旧性心梗合并慢性冠状动脉供血不足 4例, 1例显效, 心电图恢复为大致正常, 2例 ST - T改善, 1例无变化; 15例并发糖尿病 患者, 血糖, 尿糖均明显下降, 肢体麻木及口干、 多尿症状明显改善。
心绞痛控制情况: 42例治疗组患者服药前后每周心绞痛发作总次数由治疗前 395次 降至 128次( PO.001), 所有病例未见治后有症状加重者, 总效率达 92.8%; 而对照组心 绞痛发作次数由治前 215次降到 108次 (P<0.05), 总有效率为 86.6%,
结论: 松针提取物对冠心病患者可显著控制心绞痛发作次数, 改善缺血性心电图改 变, 控制心律失常的发生(室早), 并可明显降低血清总胆固醇, 轻度降低甘油三酯, 升高高密度脂蛋白, 降低 TXB2 , 升高 PGI2使冠状动脉血流量增加, 降低心肌耗氧量和 心肌后负荷, 起到保护缺血心肌作用. 六、 松针提取物抗衰老、 增加脑血流作用
以松针口 液治疗脑梗塞及老年性痴呆症患者 25例, 治疗前后检测脑血流图, 血清 过氧化脂质及铜 -锌-超氧化歧化酶(简称 SOD, ), 用药方法每次 15ml (含松针提取 物 1.6g ) , 一日三次, 疗程为 3个月。 经治疗患者脑血流图明显改善, SOD,下降, 过 氧化脂质明显减少。 (见表 12 ) 松针提取物对老年患者 SODt和过氧化脂的影响
Figure imgf000022_0002
*P<0.05 **p<0.01 ***P<0.001 月 药前患者脑血流图表现为血管阻力增加, 血流量减少, 血液流入速度减慢, 血管 弹性减慢, 血管弹性减退; 用药后 25例患者 20例脑血流图有明显改善, 表现为血管阻 力指数减少, 流入速度加快, 血流容积增加, 波形较前好转。 证明松针提取物有增加脑 血流作用。 七、 松针提取物的血管扩张作用:
离体灌流的血管环舒张试 明, 松针提取物对动脉有扩张作用, 此作用为内皮依 赖性和剂量依赖性。 在内皮存在时, 松针提取物的血管扩张作用依剂量浓度加大而逐渐 增强, 最大舒张率达 86.88±12.03% , 去内皮后仅在最高浓度时有轻度扩张作用, (14.23+2.06%). 证明松针的血管扩张作用是通过内皮细胞的舒缩血管物质实现的。 见附 图 3a-3d 。
实施例 1
松针口服液的制备
取松针 10公斤, 加水 80公斤, 加热煎煮 1.5小时, 取出药液, 药液再加水 60公斤, 加热煎煮 1小时, 取出药液, 合并两次药液, 过滤, 向滤液中加入乙醇, 静置 24小时后, 去除沉淀, 回收乙醇, 将药液浓缩至 10公斤, 加蒸饱氷稀释至 20公斤, 加入少量甜菊 甙和防腐剂尼泊金乙酯, 分装入瓶, 每支 10ml 。
实施例 2
松针胶囊剂的制备
取松针 10公斤, 葛根 3.5公斤, 加 5倍量水, 煎煮 2小时, 滤出药液, 药渣再加 4 倍量水, 煎煮 1.5小时, 滤出药液, 合并两次药液, 加乙醇静置 24小时, 去除沉淀, 回 收乙醇, 浓缩药液成浸膏状, 烘干制成干浸膏, 粉碎成细粉备用。 再取珍珠层粉 5公斤, 粉碎, 过筛制成细粉, 与上述制备的药物细粉混合均匀, 用全自动胶囊填充机装胶囊, 0.5克 /粒, 塑铝包装。
实施例 3:
制法:
取松叶 1800克和葛根 600克, 加水煎煮两次, 第一次 8倍量水, 煎煮 1.5小时, 第 二次 6倍量氷, 煎煮 1.5小时, 滤过, 合并滤液, 经干燥后得粉状物, 下面描述本发明的松针与葛根提取物的组合物(下称组合物) 的动物试验及临床试 验。
八、 組合物的血管扩张作用:
离体灌流的血管环舒张试验证明, 组合物对动脉有扩张作用, 此作用为内皮依赖性 和剂量依赖性。 在内皮存在时, 组合物血管扩张作用依剂量浓度加大而逐渐增强, 最大 舒张率达 96 % , 见图 4。 九、 组合物的降压临床试验
1、 资料与方法
观察对象: 原发性高血压 44例, 年龄均为 66岁以下成年人, 平均 53±12.7岁, 符合 WHO高血压诊断标准。 另随机选择原发性高血压 44例, 应用卡托普利治疗, 为对照组。 年龄为 59以下成年人, '平均 47±7.8岁, 2组性别、 病程见表 13 , 进入治疗前, 均停用 其它抗高血压药物 1周。 治疗方法: 组合物 1.5g, 每日 3次, 服药 5天, 若血压未降至 正常范围, 每 5天增加一次剂量 (0.5g)。 每 5天递增, 最大剂量不超过 3g, 每日 3次, 总疗程为 20天, 对照组卡托普利 25mg , 每日 3次, 若血压未降至正常范围, 亦每 5天 增加 1次剂量 (12.5mg), 每 5天递增, 最大剂量不超过 75mg, 每日 3次, 疗程同样为 20 天。
治疗高血压: 所有病例治疗前均停用其它降压药 1周, 每日测量血压 I 次. 以停用 其它降压药 1周后连续 5次 (非同日)血压平均值为治疗前血压。
治疗后血压: 开始治疗后每日测血压 1次, 用药后第 16 - 20天测 5次 (非同日)血压 平均值为治疗后血压, 每例均在治疗前及治疗结束即检查血、 尿常规、 肝肾功能、 血钾、 钠、 氯、 血脂、 血糖、 心电图等。
疗效判定标准: 显效: 治疗后舒张压下降 >1.33kpa ,并降至正常或下降 2.67kpa以上; 有效: 治疗后舒张压下降虽未达 1.33kpa , 但已降至正常或下降 1.33 - 2.53kpa。 如为收 缩期高血压, 收缩压下降〉4kpa也属有效; 无效: 治疗后血压下降未达上述标准,
2、 结果
疗效分析: 治疗前后血压及下降幅度经比较, 见表 14。 经自身对照 t检验, 组合物 组与卡托普利组均有非常显著差异 (PO.01), 2组比较无明显差异 (P>0.05)。 2组治疗后 降压疗效对比, 亦无显著差异, 见表 14 .
治疗前后心电图及血生化变化: 2组 88例治疗前有室性早搏 10例, 房性早搏 8例, 完全性左束支阻滞 4例, 完全性右束支阻滞 7例, 左心室肥厚 10例, II、 III、 avF、 V4 - V6ST - T缺血样变化 16例, 治疗后 V4 - V6ST― T缺血样变化好转 12例, 房性 早搏消失 8例, 室性早搏消失 7例, 血钾、 钠、 氯、 血糖治疗前后变化不明显。
3、 结论
组合物可显著降低原发性高血压与腎性高血压, 服药后 30分钟出现降压作用, 2小 时达高峰, 作用持续时间超过 3小时, 降压效果成剂量依赖性, 停药 20小时仍可使血压 维持在正常范围, 同时有降脂作用, 尤适用于高血压合并高血脂症患者, 用药 44例, 无 任何副作用, 总有效率为 77 % (表 15). 表 13 2组一般状况比较
Figure imgf000025_0001
*P<0.01 (自身对照) 组间对照 P<0.05
2组治疗后降压疗效对比
Figure imgf000025_0002
P>0.05(组间对照) 下面描述本发明的松针和葛根提取物与珍珠层粉組成的配方的临床试验(以下称配 方)
十、 配方治疗心肌炎的疗效观察
对象及方法 1、 治疗组: 按心肌炎诊断标准, 选择病毒性心肌炎 1 1例, 风湿性心肌炎 5例为治 疗组(共 16例) 其中男性 9例, 女性 7例, 年龄 6 - 17例 ( 1 1.6±2.8岁) , 心电图为 心肌缺血者 10例, 心律失常 9例 (表现为心动过速 6例, 频发性早搏 4例, 心动过緩 2 例) 。
2、 对照组: 病毒性心肌炎 8例, 风湿性心肌炎 4例, 共 12例, 其中男性 5例, 女 性 7例, 年龄 4 ~ 16岁(9.1±2.6岁)。 心电图心肌缺血 9例, 心律失常 7例(心动过速及 频发早搏 5例, 心动过緩 2例) 。'
3、 治疗后的空腹采血, 查血沉, GOT , CPK , CPK-MB , 心电图, 类风湿因子。
4、 治疗组给予配方 1.5g , 每日 3次; 对照組采用常规疗法: 每日静脉点滴 10 %葡 萄糖 500ml , 加维生素 C/3g, ATPMOmg , 辅酶 100u , 每日 1次, 肌注辅踏 Q101/日, 30 天为一疗程, 两组中的风湿性心肌炎均给予抗风湿常规治疗。
评定标准及统计学处理:
显效: 血沉, G0T、 CPC、 CPK - MB、 心电图及类风湿因子等均恢复至正常范 围.
有效: 以上指标较治疗明显恢复, 但尚未在正常范围 ( ECG心率异常, 心律仍有频 发早搏, 或轻度 ST - T改变。 )
无效: 以上指标虽有恢复, 但仍为明显异常,
采用显著性 T检验。
结果:
治疗后两组疗效比较, 见表 16 :
表 16
Figure imgf000026_0001
*P<0.05, **P<0.01, ***P<0.001
、 配方治疗高脂血症的疗效分析 无糖尿病、 肝肾疾病的高脂血症患者选为观察对象。 观察期间停用一切影响脂质代 谢药物, 保持平日生活饮食习惯。
1、 临床资料 110例随机分为治疗組 70例和对照组 40例, 治疗組 70例中男性 50 例, 女性 12例, 年龄 40 - 67岁, 平均年龄 55岁, 高血清胆固醇 (TC)血症 41例, 高甘 油三脂 (TG)血症 55例。 对照组 40例中男性 28例, 女性 12例, 年龄 40 - 66岁, 平均 年龄 54岁, 高 TC、 TG血症各 30例。 两组性别、 年龄、 症状基本相似, 具有可比性.
2、 分组及治疗方法
2.1 治疗组 配方 1.5g , 每日 3次, 疗程 1个月。
2.2 对照組 月见草油软胶嚢, 无锡市第六制药厂, 每粒 0.5g , 每次 2粒, 每日 3 次, 疗程 1个月。
2.3 观察方法 全部病例在治疗前和治疗结束均分别观察血、 尿常规、 肝、 肾功能, 重点观察血脂、 心电图等各项指标变化。
3、 结果
3.1 对 TC高血症的疗效: 治疗组 41例, 显效 20例, 有效 16例, 无效 5例, 总有 效率 87.8 %; 对照组 30例, 显效 4例, 有效 8例, 无效 18例, 总有效率 40 %。 两组比 较有显著性差异(X2=18.16 P<0.01)。 两組治疗前后 TC 的差值比较, 治疗组 2.46±0.69mmol/L , 对照组 0.84±0.33mmol/L, 治疗组降低 TC 的作用显著优于对照组 (t=11.86 P<0.001)。 治疗组 TC治疗前后自身比较, t=22.829 Ρ<0.001 , 说明治疗组降 4氐 TC的疗效确切。
3.2 对高 TG血症的疗效: 治疗组 55例, 显效 24例, 有效 25例, 无效 6例, 总有 效率 89.1 %; 对照组 30例, 显效 9例, 有效 5例, 无效 16例, 总有效率 46.7 % , 两组 比较有显著性差异 (X2=18.04 P<0.01)。 两组治疗前后 TG 的差值比较, 治疗组 1.57±0.52mmol/L , 对照組 1.01±0.31mmol/L , 治疗组降低 TG 的作用明显优于对照组 (t=5.385 P<0.001)。 治疗组 TG治疗前后自身比较, t=22.391 Ρ<0.001 , 说明治疗组降 低 TG的疗效确切。
配方在治疗过程中未发现不良反应, 治疗前后的血、 尿常规, 肝肾功能及心电图等 进行比较均无明显改变。
4 结论
配方治疗 TC血症、 高 TC血症总有效率分别为 87.8 %、 89.1 %。 与对照组比较有 显著性差异, 说明配方对高脂血症的疗效明显优于对照药物, 有确切的降低 TC、 TG的 作用, 与对照药物比较, 经统计学处理, P<0.001, 说明其降脂作用优于对照药物。 替换页 (细则第 26条) 十二、 配方治疗心血管病的临床试验
1、 对象与方法:
1.1 对象: 按 WHO诊断标准选择原发性高血压病、 冠心病心绞痛, 高脂血症并 高粘血症者治疗观察对象, 分为三组。
1.1.1 高血压病组: 62例, 男 37例, 女 25例, 年龄 27 - 74岁, 平均 52.3±26.5 岁, 病史 2.9±3.12年。 I、 II、 III、 期各为 18例 (29.0 % ), 40例 (64.5 % )。
1.1.2 心绞痛组: 40例, 男 21例, 女 19例, 年龄 45 - 79岁, 平均 59.8±15.2 岁, 稳定劳累型和不稳定型心绞痛分别为 26例 (65 % )和14例 (35 % )。
1.1.3 高脂血症高粘血症组: 65例, 男 42例, 女 18例, 年龄 55.3±5.0岁,
1.2 方法:
1.2.1 治疗方法: 停用其它降压药, 抗心绞痛药或降脂药, 服用配方 l~1.5g/次, 3 ^日, 疗程 4 ~ 6周, 如伴有左室肥厚, 可并用怡那林, ·如心绞痛发作, 可用硝酸脂 类或速效救心丸等, 其他常规治疗不变,
2、 结果
2.1 高血压病组: 治疗前后收缩压 (SBP)、 舒张压 (DBP)改变见表 17、 表 18。 配方降压疗效 (n=62)
Figure imgf000028_0001
替换页 (细则第 26条) 配方对各期高血压的疗效 (n=62)
Figure imgf000029_0001
2.2 心绞痛组: 症状疗效心电图疗效与不同类型的心绞痛疗效见表 19 , 表 20 。
2.3 高脂血症并高粘血症组: 血脂和血流变学治疗前后改变, 见表 21 。 表 19 配方治疗心绞痛的症状和心电图疗效 (n=40)
Figure imgf000029_0002
配方对不同类型心绞痛的疗效 (n=40)
显效 有效 总有效 无效
类型 例数 例数% 例数% 例数% 例数%
稳定劳累型 26 12 46.2 14 53.9 26 100.0
不稳定劳累型 14 8 57.1 4 28.6 12 85.7 2 4.3
合计 40 20 50.0 18 45.0 38 95.0 2 5.0
表 21 配方对血脂血流变学的影响 (n=65)
Figure imgf000030_0001
3、 讨论
应用配方治疗高血压病、 冠心病、 心绞痛、 高脂血症并高粘血症者取得了较为满 意的临床疗效, SBP、 DBP分别下降 23.4 %、 20.5 % , 总有效率 96.8 %; 心绞痛症状 和心电图疗效分别为 95 %和 65 %。 稳定劳累型和不稳定型心绞痛的有效率分别为 100 %和 85.7 % , CH、 TG , LDL - C分别下降 18.0 %、 27.2 %、 39.2 %, 而 HDL - C 却上升了 58.8 % , 红细胞压积, 全血和血浆比粘度分别降低 27.1 、 16.6 %和 24.6 % , 各项指标治疗前后对比有明显或非常显著性差异 (P<0.05 或 0.01), 表明配方确有降低血 压, 降低胆固醇、 甘油三脂、 低密度脂蛋白胆固醇、 红细胞压积、 全血和血浆比粘度, 升高高密度脂蛋白胆固醇, 保护心脏, 緩解心绞痛等疗效。

Claims

权利要求书
1、 一种松针提取物, 在固态时为浅棕色至深棕色, 溶于水, 在紫外可见光光谱中的 242nm附近有最大吸收值,
2、 治疗疾病用的权利要求 1的松针提取物, 该疾病包括高血压、 冠心病、 心绞痛、 心律失常、 心肌炎、 糖尿病、 高脂血症、 高粘血症、 高聚血症、 动脉硬化症、 脑梗塞、 脑动脉硬化症、 老年痴呆症和突发性耳聋.
3、 权利要求 2的松针提取物, 其中该疾病为高血压、 高脂血症、 高粘血症、 高聚血 症、 动脉硬化症、 脑梗塞、 脑动脉硬化症、 老年痴呆症和突发性耳聋。
4、 权利要求 2的松针提取物, 其中该疾病为冠心病、 心绞痛、 心律失常、 心肌炎和 糖尿病。
5、 权利要求 1的松针提取物在治疗高血压、 冠心病、 心绞痛、 心律失常、 心肌炎、 糖尿病、 高脂血症、 高粘血症、 高聚血症、 动脉硬化症、 脑梗塞、 脑动脉硬化症、 老年 痴呆症和突发性耳聋疾病中的应用,
6、 一种治疗疾病的方法, 包括给病人 用治疗有效量的松针组合物,
7、 一种药物組合物, 包括有效量的一种松针提取物和药物学上可接受的载体或赋形 剂.
8、权利要求 7的药物组合物,还包括一种葛根提取物,其中松针与葛根的比例为 3: 1 ~ 5: 2。
9、 权利要求 7或 8的药物组合物, 还包括珍珠层粉, 其中松针与珍珠层粉的比例为
20: 1 - 2: 1 .
10、 一种治疗疾病的方法, 包括给病人服用治疗有效量的权利要求 6的组合物,
PCT/CN1997/000006 1997-01-27 1997-01-27 Extrait d'aiguilles de pin et son utilisation WO1998032455A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR10-1999-7006766A KR100529793B1 (ko) 1997-01-27 1997-01-27 솔잎 추출물 및 이것의 용도
CA002279261A CA2279261A1 (en) 1997-01-27 1997-01-27 The extract of pine needle and the use thereof
EP97902147A EP1013278B1 (en) 1997-01-27 1997-01-27 The extract of pine needle and the use thereof
PCT/CN1997/000006 WO1998032455A1 (fr) 1997-01-27 1997-01-27 Extrait d'aiguilles de pin et son utilisation
US09/355,389 US6329000B1 (en) 1997-01-27 1997-01-27 Extract of pine needle and the use thereof
AU15884/97A AU734851B2 (en) 1997-01-27 1997-01-27 The extract of pine needle and the use thereof
JP53145598A JP2001508777A (ja) 1997-01-27 1997-01-27 松葉抽出物及びその使用
DE69734163T DE69734163T2 (de) 1997-01-27 1997-01-27 Kiefernnadelextrakt sowie dessen verwendung
HK00104348A HK1025246A1 (en) 1997-01-27 2000-07-17 The extract of pine needle and the use thereof.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN1997/000006 WO1998032455A1 (fr) 1997-01-27 1997-01-27 Extrait d'aiguilles de pin et son utilisation

Publications (1)

Publication Number Publication Date
WO1998032455A1 true WO1998032455A1 (fr) 1998-07-30

Family

ID=4574968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1997/000006 WO1998032455A1 (fr) 1997-01-27 1997-01-27 Extrait d'aiguilles de pin et son utilisation

Country Status (9)

Country Link
US (1) US6329000B1 (zh)
EP (1) EP1013278B1 (zh)
JP (1) JP2001508777A (zh)
KR (1) KR100529793B1 (zh)
AU (1) AU734851B2 (zh)
CA (1) CA2279261A1 (zh)
DE (1) DE69734163T2 (zh)
HK (1) HK1025246A1 (zh)
WO (1) WO1998032455A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006972A (ko) * 1999-04-20 2001-01-26 정동백 필수 아미노산을 다량 함유하는 소나무 추출액의 제조 방법
EP1129711A3 (en) * 2000-02-24 2001-09-12 Unilever N.V. Pinolenic acid against diabetes
JP2002045123A (ja) * 2000-08-01 2002-02-12 Nisshin Shiryo Kk 動物用飼料添加剤
CN101549013B (zh) * 2009-05-13 2012-10-03 文永盛 松丹胶囊、片剂、颗粒剂及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100468429B1 (ko) * 2001-09-07 2005-01-27 주식회사 엔바이오테크놀러지 알파-글루코시다제 저해활성이 있는 소나무 추출물 및 그추출방법
AU2003252716A1 (en) * 2002-07-29 2004-02-16 Suntory Limited Food improving blood flow
WO2005044021A1 (en) * 2003-10-30 2005-05-19 Loders Croklaan B.V. Pine needle extract
WO2005051103A1 (en) * 2003-10-30 2005-06-09 Loders Croklaan B.V. Food product comprising an extract from pine needles
KR100679676B1 (ko) * 2003-12-30 2007-02-07 김명조 잣기름 및/또는 잣박을 포함하는 잣김
KR100862383B1 (ko) * 2007-05-23 2008-10-13 주식회사영신물산 환경 친화적인 염료 및 이의 제조방법과 이를 이용한염색방법
KR100949482B1 (ko) * 2009-10-08 2010-03-24 오동석 주목과 뽕나무 추출물을 이용한 당뇨 또는 고혈압 치료용 약학 조성물 및 이의 제조 방법
KR101966983B1 (ko) * 2018-06-25 2019-04-08 주식회사 아리바이오 솔잎추출물을 함유하는 대사증후군 개선용 조성물
CN110123848A (zh) * 2019-05-30 2019-08-16 东莞怀朴植物精油有限公司 一种雪松精油的应用
KR102297900B1 (ko) * 2019-07-03 2021-09-06 경희대학교 산학협력단 소나무 껍질 추출물을 포함하는 고혈압의 예방 및 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089142A (zh) * 1993-01-04 1994-07-13 北京师范大学 松针降糖口服液
CN1097333A (zh) * 1994-06-09 1995-01-18 孙国富 一种纯植物保健制剂糖脂消及其制法
CN1099627A (zh) * 1993-08-30 1995-03-08 江苏省肿瘤防治研究所 一种用松针制备抗癌扶正冲剂的方法
CN1102111A (zh) * 1993-10-27 1995-05-03 董雍年 松针原汁的提取方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP0565313B1 (en) * 1992-04-02 1997-07-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method to improve taste preference of pine extract, and orally administrable product obtained thereby
CN1100605A (zh) * 1993-09-22 1995-03-29 广元市荣鑫食品总公司 一种保健饮料及其生产方法
CN1101275A (zh) * 1994-04-15 1995-04-12 郑毅 治疗心、脑血管性疾病的中药液及其生产方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089142A (zh) * 1993-01-04 1994-07-13 北京师范大学 松针降糖口服液
CN1099627A (zh) * 1993-08-30 1995-03-08 江苏省肿瘤防治研究所 一种用松针制备抗癌扶正冲剂的方法
CN1102111A (zh) * 1993-10-27 1995-05-03 董雍年 松针原汁的提取方法
CN1097333A (zh) * 1994-06-09 1995-01-18 孙国富 一种纯植物保健制剂糖脂消及其制法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""THE EFFECT OF PINE NEEDLE ON LONGEVITY OF VINEGAR FLY"", JOURNAL OF ZHEJIANG COLLEGE OF TCM, XX, CN, vol. 16, no. 06, 1 January 1992 (1992-01-01), CN, pages 49/50, XP002908965 *
HU JUN, ET AL.: ""THE STUDY OF BLOOD LIPID LOWERING EFFECT OF PINE NEEDLE"", JOURNAL OF ZHEJIANG COLLEGE OF TCM, XX, CN, vol. 16, no. 03, 1 January 1992 (1992-01-01), CN, pages 30/31, XP002908966 *
See also references of EP1013278A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006972A (ko) * 1999-04-20 2001-01-26 정동백 필수 아미노산을 다량 함유하는 소나무 추출액의 제조 방법
EP1129711A3 (en) * 2000-02-24 2001-09-12 Unilever N.V. Pinolenic acid against diabetes
JP2002045123A (ja) * 2000-08-01 2002-02-12 Nisshin Shiryo Kk 動物用飼料添加剤
CN101549013B (zh) * 2009-05-13 2012-10-03 文永盛 松丹胶囊、片剂、颗粒剂及其制备方法和应用

Also Published As

Publication number Publication date
KR20010049156A (ko) 2001-06-15
DE69734163T2 (de) 2006-08-24
KR100529793B1 (ko) 2005-11-23
JP2001508777A (ja) 2001-07-03
US6329000B1 (en) 2001-12-11
EP1013278A1 (en) 2000-06-28
AU1588497A (en) 1998-08-18
DE69734163D1 (de) 2005-10-13
AU734851B2 (en) 2001-06-21
EP1013278A4 (en) 2002-03-27
HK1025246A1 (en) 2000-11-10
CA2279261A1 (en) 1998-07-30
EP1013278B1 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
JP4657714B2 (ja) 心疾患用の組成物、その組成物を調製する方法、及びそれらの使用。
WO1998032455A1 (fr) Extrait d&#39;aiguilles de pin et son utilisation
CN101033245B (zh) 具栖冬青苷的制备方法及应用
CN102908583A (zh) 一种治疗胸痹心痛的中药组合物及其制备方法、质量检测方法和用途
CN107648430A (zh) 一种含延龄草甾体皂苷类有效成分胶囊制剂的制备方法及其在制备各类药物中的应用
CN1931236B (zh) 一种由丹参和红景天制成的药物组合物
CN1931217B (zh) 一种由银杏叶与红景天制成的药物组合物
CN104435034B (zh) 一种三七总皂苷及其制备方法
NO160206B (no) Fremgangsmaate ved fremstilling av isosilybinfri silibinin.
CN1558768A (zh) 一种中药组合物及其制备方法
CN103566282B (zh) 一种抗肿瘤作用中药组合物及制备方法
CN101879272B (zh) 一种治疗冠心病的中药复方及其制备方法与应用
CN100467025C (zh) 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途
CN1935178A (zh) 银杏叶提取物与淫羊藿提取物的组合物
CN101176770B (zh) 银杏叶与蒲黄的药用组合物
CN100531740C (zh) 一种辅助防治心、脑血管疾病的保健品
CN101161268B (zh) 丹参和蒲黄的药用组合物
KR100504966B1 (ko) 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물
CN101239086B (zh) 一种治疗心脑血管病的注射剂的制备方法
CN102475778B (zh) 一种治疗原发性高血压的中药组合物的制备方法
CN102475780B (zh) 一种治疗原发性高血压的中药组合物的制备方法
CN110812462A (zh) 一种祛瘀通脉消斑的中药组合物及其应用
CN101161269A (zh) 蒲黄或其提取物和山楂叶或其提取物的药物组合物
KR100213667B1 (ko) 항당뇨 효과를 가지는 조성물
CN112274557A (zh) 冬凌草叶水提物粉末,其制备,抗动脉血栓作用及应用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181548.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2279261

Country of ref document: CA

Ref document number: 2279261

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1998 531455

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997006766

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997902147

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09355389

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997902147

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997006766

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019997006766

Country of ref document: KR

Ref document number: 1997902147

Country of ref document: EP